# Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)

> **NCT04328961** · PHASE2,PHASE3 · COMPLETED · sponsor: **University of Washington** · enrollment: 943 (actual)

## Conditions studied

- COVID-19
- Corona Virus Infection
- SARS (Severe Acute Respiratory Syndrome)
- SARS-CoV-2

## Interventions

- **DRUG:** Hydroxychloroquine Sulfate
- **DRUG:** Ascorbic Acid

## Key facts

- **NCT ID:** NCT04328961
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-31
- **Primary completion:** 2020-09-24
- **Final completion:** 2020-10-08
- **Target enrollment:** 943 (ACTUAL)
- **Last updated:** 2021-12-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04328961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04328961, "Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04328961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*